Publications by authors named "E Girodon"

Claim this Profile
S
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies.
Pierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, Isabelle Durieu, Martine Reynaud-Gaubert

Lancet Respir Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.
Iwona Pranke, Valeria Capurro, Benoit Chevalier, Emanuela Pesce, Valeria Tomati, Emmanuelle Girodon

Front Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two Class I variants: real-world data from the French compassionate programme.
Pierre-Régis Burgel, Emmanuelle Girodon, Neeraj Sharma, Caroline Raynal, Jennifer Da Silva

EClinicalMedicine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary proposals for the follow-up of infants born to mothers with cystic fibrosis treated with CFTR modulators during the first two years of life.
Philippe Reix, Camille Audousset, Emmanuelle Girodon, Isabelle Sermet Gaudelus, Sophie Gautier

Arch Pediatr· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, Isabelle Durieu, Véronique Houdouin

Lancet Respir Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis